

What is claimed is

1. A combination comprising as active ingredients;
  - (i) a renin inhibitor or a pharmaceutically acceptable salt thereof;
  - (ii) a least one PDGF receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof.
2. The combination according to claim 1 wherein the PDGF receptor tyrosine kinase inhibitors are selected from 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide methanesulfonate, 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, CT52923, (4-(6,7-dimethoxy-4-quinazolinyl)-N-(3,4-methylenedioxybenzyl)-1-piperazinethiocarboxamide), RP-1776, GFB-111, pyrrolo[3,4-c]-beta-carboline-diones, SU 102, AG1296, AG1296 and RPR101511A or, in each case, a pharmaceutically acceptable salt thereof.
3. The combination according to claim 1 or claim 2 wherein the renin inhibitor is selected from 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, detikiren, terlakiren and zankiren, or a pharmaceutically acceptable salt thereof.
4. The combination according to claim 1 or claim 2 wherein the renin inhibitor is 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide, or a pharmaceutically acceptable salt thereof.
5. A combination comprising as active ingredients;
  - (i) 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide or a pharmaceutically acceptable salt thereof; and
  - (ii) a PDGF receptor tyrosine kinase inhibitor selected from N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and 4-Methyl-N-[3-

(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, or in each case a pharmaceutically acceptable salt thereof.

6. The combination according to claim 4 or claim 5 wherein the active ingredient (i) is in the form of its hemi-fumarate salt, and the active ingredient (ii) is in the form of a its monomesylate salt.

7. The combination according to any of claims 1 to 6 in the form of a combined preparation or a pharmaceutical composition.

8. The present invention also relates to a method for the prevention, delay of progression or treatment of a disease and disorder selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, Nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance, comprising administering to a warm-blooded animal, including man, in need thereof jointly therapeutically effective amounts of a combination according to any one of claims 1 to 7.

9. The present invention relates to the use of a renin inhibitor preferably of formula (I) or a pharmaceutically acceptable salt thereof in combination with a least one PDGF receptor tyrosine kinase inhibitor or a pharmaceutically acceptable salt thereof;

for the manufacture of a medicament for the prevention, delay of progression or treatment of a disease and disorder selected from selected from cancer, thrombosis, psoriasis, fibrosis, dermatosclerosis, atherosclerosis, restenosis, cardiovascular hypertrophy or cardiovascular hypertrophic remodeling or hypertension-induced cardiovascular diseases, cardiac hypertrophy, cardiac remodeling after myocardial infarction, pulmonary congestion and cardiac fibrosis in dilated or in hypertrophic cardiomyopathy, left or right ventricular hypertrophy, diabetic myopathy, stroke prevention in congestive heart failure, hypertrophic medial thickening in arteries and/or in large vessels, hypertension-induced vascular injuries, mesenteric vasculature hypertrophy, renal hyperfiltration such as after portal renal ablation, proteinuria in chronic renal disease, renal arteriopathy as a consequence of hypertension, Nephrosclerosis or hypertensive nephrosclerosis, mesangial hypertrophy, hypertension, congestive heart failure, diabetes, especially type 2 diabetes mellitus, diabetic retinopathy, macular degeneration, diabetic nephropathy, glomerulosclerosis, chronic renal failure, diabetic neuropathy, syndrome X, premenstrual syndrome, coronary heart disease, angina pectoris, myocardial infarction, stroke, vascular restenosis, macular degeneration, cataracts, premenstrual syndrome, skin and connective tissue disorders, endothelial dysfunction and impaired vascular compliance.

10. A kit of parts comprising

- (i) an amount of a renin inhibitor in a first unit dosage form;
- (ii) an amount of at least one PDGF receptor tyrosine kinase inhibitor, or, in each case, where appropriate, a pharmaceutically acceptable salt thereof, in the form of two or three or more separate units of the components (i) to (ii).

11. The use according to claim 9, a kit of parts according to claim 10, wherein the renin inhibitor is selected from the group consisting of aliskiren, detikiren, terlakiren, and zankiren.

12. The use according to claim 9 or 11, the kit of parts according to claim 10 or 11, wherein the PDGF receptor tyrosine kinase inhibitors are selected from 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide, 4-(4-methylpiperazin-1-ylmethyl)-N-[4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino]phenyl]-benzamide methanesulfonate, 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, CT52923, (4-(6,7-dimethoxy-4-quinazolinyl)-N-(3,4-methylenedioxybenzyl)-1-piperazinethiocarboxamide), RP-

1776, GFB-111, pyrrolo[3,4-c]-beta-carboline-diones, SU 102, AG1296, AG1296 and RPR101511A or, in each case, a pharmaceutically acceptable salt thereof.

13. The use according to claim 9, or the kit of parts according to claim 10, wherein the active ingredient

- (i) is 2(S),4(S),5(S),7(S)-N-(3-amino-2,2-dimethyl-3-oxopropyl)-2,7-di(1-methylethyl)-4-hydroxy-5-amino-8-[4-methoxy-3-(3-methoxy-propoxy)phenyl]-octanamide or a pharmaceutically acceptable salt thereof; and/or
- (ii) is a PDGF receptor tyrosine kinase inhibitors selected from N-{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine and 4-Methyl-N-[3-(4-methyl-imidazol-1-yl)-5-trifluoromethyl-phenyl]-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-benzamide, or in each case a pharmaceutically acceptable salt thereof.

14. The use or the kit of parts according to claim 13, wherein the active ingredient (i) is in the form of its hemi-fumarate salt and the active ingredient (ii) is in the form of its monomesylate salt.